Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Busan
Clinical trial register · South Korea

Clinical Trials in Busan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 195 Goyang-si 72 Daegu 59 Seongnam-si 59 Busan 50
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca50 Janssen Research & Development, LLC30 Eli Lilly and Company23 AbbVie19 Novartis Pharmaceuticals16 Clear sponsor filter
Site location
Seoul195 Goyang-si72 Daegu59 Seongnam-si59 Busan50
All 52 locations
Target enrolment
to

Trials with a site in Busan

50 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
AstraZeneca
Phase 3
950
Busan, Daegu, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul, Yangsan
2026-09-16
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon, Seongbuk-Gu, Seoul
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Guri-si, Junggu, Seoul
2026-08-21
Recruiting
AstraZeneca
Phase 3
1,500
Busan, Daegu, Daejeon, Incheon, Seoul, Suwon
2026-08-20
Recruiting
AstraZeneca
Phase 3
1,200
Busan, Changwon-si, Daegu, Daejeon, Guri-si, Incheon, Seoul
2026-07-06
Recruiting
AstraZeneca
Phase 3
4,500
Busan, Daegu, Goyang-si, Gyeonggi-do, Incheon, Jongno-gu, Seoul, Suwon
2026-06-29
Recruiting
Danicopan PMS in Korea
NCT07457151Paroxysmal Nocturnal Hemoglobinuria
AstraZeneca
Observational
27
Busan, Hwasun-gun, Seoul
2026-04-10
Recruiting
AstraZeneca
Phase 3
1,100
Busan, Daegu, Goyang-si, Seongnam-si, Seoul, Suwon, Yangsan
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Busan, Daegu, Seongnam-si, Seoul
2025-12-04
Recruiting
AstraZeneca
Observational
130
Busan, Daejeon, Goyang-si, Guri-si, Incheon, Seongnam-si, Seoul, Suwon
2025-10-15
Recruiting
AstraZeneca
Phase 3
700
Busan, Daegu, Goyang-si, Seongnam-si, Seoul
2025-08-06
Active, closed
AstraZeneca
Phase 1
9
Busan, Seoul
2025-07-28
Recruiting
AstraZeneca
Phase 3
15,100
Bucheon-si, Busan, Changwon-si, Daegu, Daejeon, Goyang-si, Gwangju, Gwangmyeong
2025-06-04
Active, closed
AstraZeneca
Phase 3
3,103
Anyang-si, Bucheon-si, Busan, Changwon-si, Cheonan-si, Daegu, Daejeon, Gangwon-do
2025-05-28
Recruiting
AstraZeneca
Phase 3
1,220
Busan, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul
2025-05-06
Recruiting
Imjudo & Imfinzi PMS
NCT06544629Hepatocellular Carcinoma
AstraZeneca
Observational
246
Busan, Goyang, Seongnam, Seoul, Suwon
2025-04-14
Recruiting
AstraZeneca
Phase 3
5,000
Ansan-si, Anyang-si, Busan, Cheonan-si, Goyang-si, Gwangju, Seongnam-si, Seoul
2025-03-03
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Busan, Seoul
2025-01-30
Recruiting
AstraZeneca
Phase 3
744
Busan, Chungcheongbuk-do, Goyang-si, Gyeonggi-do, Jinju, Seoul, Suwon
2024-10-04
Recruiting
AstraZeneca
Phase 3
620
Busan, Gyeonggi-do, Hwasun-gun, Seongnam-si, Seoul
2024-08-12
Recruiting
AstraZeneca
Phase 3
1,018
Busan, Goyang-si, Jeonnam, Seoul
2024-08-07
Recruiting
AstraZeneca
Phase 2
80
Busan, Daegu, Gyeongsangnam-do, Incheon, Jeonju, Seogu, Seoul, Suwon
2024-07-16
Recruiting
Real-World Treatment Study of Koselugo (Selumetinib)
NCT06360406Neurofibromatosis 1, Neurofibroma, Plexiform
AstraZeneca
Observational
200
Busan, Chungcheongbuk-do, Daejeon, Gyeonggi-do, Incheon, Jeonnam, Seoul, Wŏnju
2024-06-15
Recruiting
AstraZeneca
Phase 3
3,850
Anyang-si, Bucheon-si, Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gwangmyeong
2024-04-12
Active, closed
AstraZeneca
Phase 3
2,554
Ansan-si, Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Gwangju, Seoul
2024-03-29
Recruiting
AstraZeneca
Phase 3
5,250
Anyang-si, Busan, Daegu, Gwangju, Jeonju, Seoul, Uijeongbu-si, Ulsan
2024-02-21
Recruiting
AstraZeneca
Phase 3
625
Busan, Daegu, Goyang-si, Seongnam-si, Seoul
2023-11-23
Active, closed
AstraZeneca
Phase 3
314
Busan, Seoul
2023-11-08
Active, closed
AstraZeneca
Phase 3
1,835
Ansan-si, Busan, Cheonan-si, Daegu, Goyang-si, Seoul
2023-11-07
Active, closed
AstraZeneca
Phase 2
60
Anyang-si, Busan, Daegu, Seoul
2023-07-18
Recruiting
AstraZeneca
Phase 3
4,300
Busan, Daegu, Donggu, Goyang-si, Jeonnam, Seongbuk-Gu, Seoul
2023-03-31
Active, closed
AstraZeneca
Phase 2
188
Busan, Cheongju-si, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Seongnam-si, Seoul
2023-03-06
Active, closed
AstraZeneca
Phase 3
1,350
Busan, Cheongju-si, Jinju, Seoul, Suwon
2022-12-29
Active, closed
AstraZeneca
Phase 3
1,174
Busan, Daegu, Goyang-si, Seongnam-si, Seoul
2022-11-28
Active, closed
AstraZeneca
Phase 3
644
Busan, Daegu, Seoul
2022-05-16
By invitation
AstraZeneca
Phase 3
214
Busan, Gwangju, Seoul
2022-04-19
Recruiting
AstraZeneca
Phase 2
630
Busan, Chungcheongbuk-do, Seongnam-si, Seoul, Suwon
2022-04-14
Active, closed
AstraZeneca
Phase 3
760
Busan, Daegu, Goyang-si, Junggu, Seoul
2022-03-28
Active, closed
AstraZeneca
Phase 3
1,035
Bukgu, Busan, Goyang-si, Seoul
2022-03-25
Active, closed
AstraZeneca
Phase 3
712
Busan, Goyang-si, Incheon, Seongnam-si, Seoul
2021-08-05
Active, closed
AstraZeneca
Phase 3
1,371
Busan, Daegu, Goyang-si, Seoul
2021-01-28
Active, closed
AstraZeneca
Phase 1/2
245
Busan, Seoul
2020-12-28
Active, closed
AstraZeneca
Phase 3
370
Busan, Cheongju-si, Goyang-si, Seongnam-si, Seoul
2020-10-02
Active, closed
AstraZeneca
Phase 3
818
Busan, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul, Suwon
2020-04-16
Active, closed
AstraZeneca
Phase 3
923
Busan, Cheonan-si, Cheongju-si, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2019-06-25
Active, closed
AstraZeneca
Phase 3
825
Busan, Cheongju-si, Seongnam-si, Seoul, Suwon
2018-12-06
Active, closed
AstraZeneca
Phase 3
724
Busan, Daegu, Goyang-si, Seoul
2018-11-30
Active, closed
AstraZeneca
Phase 3
1,324
Ilsan, Seongnam-si, Busan, Daegu, Seoul
2017-10-11
Active, closed
AstraZeneca
Phase 3
1,186
Busan, Chungcheongbuk-do, Daegu, Incheon, Seongnam-si, Seoul, Ulsan
2017-06-01
Active, closed
AstraZeneca
Phase 3
1,118
Busan, Changwon-si, Cheongju-si, Daegu, Daejeon, Goyang-si, Incheon, Jinju
2015-07-21
Rows per page Showing 1–50 of 50
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/busan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 50 of those studies with a site in Busan that also match the filters currently applied.

How many clinical trials are recruiting in Busan?

26 of the 50 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 23 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Busan), 50 studies
PhaseStudiesRecruitingShare
Phase 3391978%
Observational448%
Phase 2428%
Phase 1/2214%
Phase 1102%

Most active sponsors

Lead sponsors with the most studies (Busan)
Lead sponsorStudiesRecruiting
AstraZeneca5026
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.